Who are intensive chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, ATRA+Chemo, Oxaliplatin (OXAL), irinotecan + Carboplatin + erbitux, FOLFIRI + cetuximab, Adjuvant chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intensive-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

intensive chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

intensive chemotherapy (intensive chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy. Area: Oncology.

phase 3 Chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

intensive chemotherapy (intensive chemotherapy) — University Hospital, Toulouse. Intensive chemotherapy involves the use of high doses of chemotherapy drugs to kill cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intensive chemotherapy TARGET	intensive chemotherapy	University Hospital, Toulouse	phase 3	Chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
ATRA+Chemo	ATRA+Chemo	Shanghai Jiao Tong University School of Medicine	marketed	Retinoid + chemotherapy combination	Retinoic acid receptor (RAR)
Oxaliplatin (OXAL)	Oxaliplatin (OXAL)	Memorial Sloan Kettering Cancer Center	marketed	Platinum-based chemotherapy agent	DNA
irinotecan + Carboplatin + erbitux	irinotecan-carboplatin-erbitux	Pfizer	marketed	chemotherapy	topoisomerase I, platinum DNA damage, epidermal growth factor receptor
FOLFIRI + cetuximab	FOLFIRI + cetuximab	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	marketed	Chemotherapy combination + monoclonal antibody	EGFR (epidermal growth factor receptor); DNA (via FOLFIRI)
Adjuvant chemotherapy	Adjuvant chemotherapy	Institut de Cancérologie de Lorraine	marketed	Chemotherapy regimen (multi-agent or single-agent cytotoxic)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy class)

University Hospital, Rouen · 2 drugs in this class
Sun Yat-sen University · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
Delcath Systems Inc. · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Prof. Dr. med. Claus Rödel · 1 drug in this class
Prothena Biosciences Ltd. · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). intensive chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/intensive-chemotherapy. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing